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Background: Obesity is a state of subclinical inflammation resulting in loss of function of insulin receptors and
decreased insulin sensitivity. Inhibition of the inflammatory enzymes, matrix metalloproteinases (MMPs), for
6 months in rodent models restores insulin receptor function and insulin sensitivity.
Methods: This 12-week double-blind, randomized, placebo (PL)-controlled proof-of-concept study was performed
to determine if the MMP inhibitor (MMPI), doxycycline, decreased global markers of inflammation and enhanced
muscle insulin sensitivity in obese people with type 2 diabetes (DM2). The study included non-DM2 controls
(n = 15), and DM2 subjects randomized to PL (n = 13) or doxycycline 100 mg twice daily (MMPI; n = 11). All
participants were evaluated on Day 1; MMPI and PL groups were also evaluated after 84 days of treatment.
Results: There was a significant decrease in inflammatory markers C-reactive protein (P < 0.05) and myeloperoxidase
(P = 0.01) in the MMPI but not PL group. The MMPI also significantly increased skeletal muscle activated/total insulin
signaling mediators: 3’phosphoinositide kinase-1 (PDK1) (p < 0.03), protein kinase B (PKB/Akt) (p < 0.004), and
glycogen synthase kinase 3ß (GSK3ß) (p < 0.03).
Conclusions: This study demonstrated short term treatment of people with diabetes with an MMPI resulted in
decreased inflammation and improved insulin sensitivity. Larger, longer studies are warranted to determine if
doxycycline can improve glucose control in people with diabetes.
Trial Registration: Clinicaltrials.gov NCT01375491
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As early as 1993, obesity was recognized as a heightened
state of inflammation with inflammatory cells increasing
within enlarging adipose tissue depots [1]. As part of in-
flammation, expression levels and activity of matrix
metalloproteinases (MMPs), a family of extracellular
endopeptidases, are significantly elevated in rodent* Correspondence: Karen.herbst@va.gov
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distribution, and reproduction in any mediummodels of obesity [2] and obese humans. [3-5] MMPs,
ubiquitously found in tissue and secreted by immune
cells, cleave extra-cellular matrix components of body
tissues and other proteins during wound repair, tissue
remodeling, cancer growth and metastases, and inflam-
mation. MMPs reported to be elevated in obesity com-
pared to healthy control populations include MMP-2,
-3,-8 and −9, with less elevation of MMP-7 [3] [6], the
latter thought to be a marker of adipocyte maturity [7].
In animal models of diabetes and hypertension, exces-
sive proteolytic MMP activity cleaves the extracellular
domain of the insulin receptor, as well as other recep-
tors, resulting in loss of function, including a reductiontral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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MMP inhibitor (MMPI) therefore improved not only
MMP levels and activity but blood glucose levels by
33% in mice. [9] Regulation of MMPs is, however,
complex, where transcriptional regulators and tissue
inhibitors of MMP (TIMPs) modulate MMP levels
and activity, respectively. Only examining MMP
levels may therefore, not provide complete informa-
tion. For example, MMP-2 and MMP-9 decreased
after exercise-induced weight loss [10,11] but in a
separate study, MMP-2 and MMP-3 levels did not
decline after bariatric surgery. [7] Clinical outcome
studies are therefore warranted to determine whether
MMP inhibition reduces inflammation and improves
insulin sensitivity in obese diabetic patients.
Doxycycline, a synthetic derivative of tetracycline, is a
broad spectrum inhibitor of MMP-1, -2, -3, -8, -9, -10,
and −13 [9,12-15]. Doxycycline has been used success-
fully as an MMPI in a number of pathological states in
which MMPs are known to be elevated. For example,
doxycycline significantly reduced progressive aortic de-
generation after aneurysm repair along with MMP-9
levels in human subjects after 6 months of treatment
[16]. Doxycycline was also more effective than a beta-
blocker at preventing thoracic aortic aneurysm develop-
ment in Marfan syndrome through inhibition of MMP-2
and −9 [15]. Golub et al. also demonstrated inhibition of
MMP activity in rodent models of DM2 by MMPIs of
which doxycycline was the most potent. [14,17]
A means to determine if MMPI translates into
improved insulin sensitivity in diabetic patients is to as-
sess the activity of molecules in the insulin signaling
pathway in skeletal muscle. Insulin binding to its recep-
tor activates phosphatidyl inositol-3-kinase (PI3K)
resulting in recruitment and phosphorylation of PDK1
(pPDK1), which in turn phosphorylates and activates
Akt (pAkt). [18] pAkt triggers an increase in insulin re-
sponsive glucose transporter (GLUT4) translocation and
recruitment to the cell membrane, increasing glucose
uptake by the cell. pAkt also phosphorylates and thus
inactivates GSK3β (pGSK3β). This prevents GSK3β from
phosphorylating (and thus inactivating) glycogen syn-
thase – which leaves the glycogen synthase active to
continue glycogen production. Enhancement of insulin
sensitivity in muscle, therefore, should increase levels of
pPDK1, pAkt and pGSK3β.
In a proof of concept clinical trial we determined
whether doxycycline (MMPI) can reduce inflammation
and improve insulin sensitivity. For this purpose, we en-
rolled DM2 patients into a double-blind randomized,
short-term, clinical trial to receive 84 days of either
MMPI or PL. Markers of inflammation and muscle insu-
lin signaling mediators were measured before and after
treatment and compared to placebo controls.Methods
Eligibility and exclusion criteria
Participants were eligible if they had DM2 <10 years
with A1c 7.5-10%, no or stable retinopathy, and nor-
mal creatinine. Because this was a proof of concept
study, participants could use any hypoglycemic medi-
cation including insulin but not thiazolidinediones,
which are known to inhibit MMPs [19]. Using pub-
lished data on relative MMP-9 levels [20], we esti-
mated a power greater than 99% at a two-sided
alpha of 5% to see a difference in mean C-reactive
protein (CRP) and MMP levels between DM groups
with 15 subjects per group.
Study design
This study was approved by the University of California,
San Diego (UCSD) Human Research Protection Program
and the Research and Development Committee at the
Veterans Affairs San Diego Healthcare System which
support research that is in compliance with the Helsinki
Declaration as part of the United States’ Office for
Human Research Protections. All participants completed
an informed consent process prior to enrollment. The
study was a double-blind, randomized, PL-controlled
trial of the oral antibiotic, doxycycline, compared to PL
in obese patients with DM2. The participants with DM2
were randomly assigned to either 100 mg doxycycline
(MMPI) twice daily or PL until day 84 (D84). The main
inflammatory outcome measures, CRP and myeloperoxi-
dase (MPO) levels, were measured at baseline (day 1; D1)
and D84. Muscle biopsies for total and phosphorylated
PDK1, Akt, and GSK3β were obtained for 7 consecutive
participants in the PL and MMPI groups on D1 and D84,
directly after a 180-minute oral glucose tolerance test
(OGTT; a relative insulin-stimulated state). We did not ex-
pect body composition changes in this short study but
completed dual-energy x-ray absorptiometry (DXA) scans
on D1 and D84 to confirm that any changes in muscle in-
sulin sensitivity were not due to changes in body compos-
ition. While we did not expect change in global measures
of glucose homeostasis in this short proof of concept study,
based on the much longer time needed to see changes in
these parameters in rodent studies, [9] we did assess
hemoglobin A1c (A1c), calculated indices from the OGTT
and used calculations from the homeostasis model assess-
ment (HOMA) on D1 and D84 as comparators for future
studies. Additional inflammatory markers measured on D1
and D84 included a cytokine array. Creatinine levels, the
liver enzyme, AST, and a lipid panel as safety labs, and vital
signs were measured on D1 and D84. Healthy control parti-
cipants (controls), enrolled to provide comparison data for
people without DM2, underwent screening and D1 visits
only.
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The skin was sterilely prepped and draped over the vas-
tus lateralis 7 cm caudal to the medial patellar line.
Lidocaine (10 cc) was infused superficially then deep
and the skin incised 5 mm with a scalpel. A trochanter
was used to obtain 400 mg of muscle that was immedi-
ately flash frozen in liquid nitrogen. Cyanoacrylates were
used to close the wound followed by firm pressure and a
compression wrap.
MMP level and activity
Plasma samples from the OGTT time zero were mixed
for 30 min with 0.5 mg/mL of a charge-changing peptide
substrate for MMP-2 and MMP-9 (Ac-NGDPVGLTA-
GAGK-NH2 [synthesized by Aapptec (Louisville, KY)
and labeled with Bodipy FL-SE (Invitrogen)]) then
loaded into 20% polyacrylamide gels and electrophoresed
for 10 minutes prior to imaging as previously described.
[21] A global assay for MMP activity levels was also per-
formed on plasma samples using the SensoLyteW520
Generic MMP assay kit according to manufacturer’s
instructions (#71158; AnaSpec, San Jose, CA.).
Western immunoblotting
Total proteins were extracted from muscle biopsies of 7
consecutive PL and 7 MMPI participants, in the pres-
ence of a mix of protease and phosphatase inhibitors
(Thermo Scientific, Waltham, MA), which were separated
by SDS-polyacrylamide gel electrophoresis (NuPAGE
4–12% polyacrylamide Bis-Tris, Invitrogen) and trans-
ferred to PVDF membranes. Primary antibodies used for
immunoblotting included total Akt and phospho Akt
(Thr308); total PDK1 and phospho PDK1; total GSK3β and
phospho GSK3β; and GAPDH (Cell Signaling Technology,
Danvers, MA.). Incubation of the immunoblots with horse-
radish peroxidase-conjugated secondary antibodies was car-
ried out after membranes were incubated with their
corresponding primary antibodies. The immunoblots were
detected with Western lightning enhanced chemilumines-
cence detection reagent (PerkinElmer LAS, Inc., Norton,
OH). Band intensity was quantified with Scion ImageJ
Software for personal computers (Scion, Frederick, MD)
and expressed in arbitrary units. Day 84 values were nor-
malized relative to baseline values equal to 1. GAPDH was
used as an internal standard.
Oral glucose tolerance test (OGTT)
The OGTT was performed once in all participants on
D1 and on D84 in subjects with DM2 according to pub-
lished guidelines. [22] Following an overnight fast, 75
grams of liquid carbohydrate was administered over a
span of 5 minutes or less, with blood samples obtained
via heparin lock at −20, -10, 0, 15, 30, 60, 90, 120, and180 min to determine glucose concentrations using a
glucose analyzer (YSI Life Sciences, Yellow Spring, OH)
and insulin levels. Plasma insulin levels were measured
on stored frozen (−80°C) samples by double-antibody
sandwich electro chemiluminescence immunoassay
(ECLIA; cat#L45CA-1; Meso Scale Diagnostics [MSD],
Gaithersburg, MD, USA) on Sector Imager 2400
(SI2400; MSD, Gaithersburg, MD, USA) by the UCSD
Core laboratory. Data was analyzed for measures of in-
sulin sensitivity and glucose utilization using published
methods. [23]
Glucose homeostasis
Homeostasis Model Assessment of insulin secretion
(HOMA-IS) was calculated as 20 fasting insulin=7:175ð Þ=½
fasting glucose 3:5ð Þ [24,25] and HOMA-IR as fasting½
insulin pmol=lð Þfasting glucose mmol=lð Þ=135: The early
secretory response of insulin to an oral glucose load (Δin-
sulin30–0/Δglucose30–0) was calculated as [Δ insulin
(30 min− 0 min)]/[Δ glucose (30 min− 0 min)] [26]. The
incremental (above the baseline value) area under the
curve (AUCi) for glucose and insulin was calculated using
GRAPHPAD 5.0.
Dual X-ray absorptiometry (DXA)
Fat and fat-free mass were measured by DXA scan for
whole-body composition on a Hologic Discovery W
(Boston, MA) in the UCSD Clinical Trials and Research
Institute (CTRI) and analyzed using software QDR
DICOM for Windows XP.
Other laboratory methods
Serum AST, creatinine, total cholesterol, triglycerides,
HDL, LDL, and A1c were measured at UCSD laboratories
using established procedures.
Biomarkers
Assays were performed on plasma samples stored in −80
degree refrigerators according to manufacturer’s kit instruc-
tions. MPO ELISA assay (#30-6613A; ALPCO, Salem, NH),
serum cytokines (Millipore, Billerica, MA), CRP ELISA
(#DCRP00; R&D Systems, Inc., Minneapolis, MN).
Statistical methods
Randomization to PL or MMPI was in blocks of two
using Research Randomizer. [27] Data are presented as
average ± SEM. Paired t-tests for pre- and post-
treatment values, t-tests between the PL and MMPI
groups, and AUC for insulin and glucose values obtained
from the OGTT were performed using commercial soft-
ware (GraphPad Prism version 5.00, GraphPad Software,
San Diego California USA, www.graphpad.com). For
MMP 2/9 activity analyses, a Wilcoxon signed rank test
and sign tests were used for paired comparisons. For 3
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control vs. PL D84 vs. MMPI D84), a Kruskal-Wallis test
was used, followed by post-hoc Mann–Whitney-Wilcoxon
tests with a Bonferroni correction (SPSS). Post-hoc
analyses were performed in order to determine
which pair(s) of groups within that set explained the
statistical significance. A p-value of .05 was used as
the criterion for declaring statistical significance,




A total of 39 participants enrolled in this study including
15 controls without DM2 whose data served as compari-
son values for D1 data obtained from participants with
DM2. Twenty-four controls were consented, three did
not qualify and six failed to show for D1 procedures.
Thirty-three participants with DM2 were enrolled, three
did not qualify, three were unable to start the study due
to medical problems and three failed to show for D1
procedures. Thirteen participants with DM2 were rando-
mized to the PL group and eleven were randomized to
the MMPI group. One subject in the PL group dropped
out due to a skin yeast infection and one participant
dropped from the MMPI group because of sun sensitiv-
ity. A second subject developed joint aches, night sweats,
nausea and dizziness after MMPI treatment which
resolved after stopping the drug. Two patients on MMPI
developed nausea but completed the study.
There were no significant differences between baseline
characteristics for the DM2 participants (Table 1). Statis-
tically significant differences between the control andTable 1 Baseline characteristics of study participants
(Mean±SEM)
Characteristics Control Placebo Doxycycline
Sample size 15 13 11
Age (years) 48.7 ± 3.1 54.5 ± 1.7 55.3 ± 1.9
Females (%) 5 (0.33) 2 (0.15) 2 (0.18)
Weight (kg) 79.1 ± 3.6 121.6 ± 6.4** 116.8 ± 9.7**
Total Lean Mass (kg) 52.5 ± 17.5 75.5 ± 15.3** 66.7 ± 13.8*
Total Fat Mass (kg) 20.1 ± 5.8 40.7 ± 10.3** 37.8 ± 13.3
BMI (kg/m2) 26.8 ± 0.86 39.7 ± 1.4** 37.9 ± 2.6**
Fasting Glucose (mg/dL) 90.8 ± 7.4 178.2 ± 43.8** 149.4 ± 53.4**
Insulin (uIU/mL) 4.0 ± 1.9 41.0 ± 35.1** 39.4 ± 43.2*
A1c (%) 5.4 ± 0.06 8.5 ± 0.4** 8.2 ± 0.5**
Race or ethnic group no. (%)
Non-Hispanic white 13 (87) 13 (100) 9 (82)
Black 1 (7) 0 (0) 1 (9)
Hispanic 1 (7) 0 (0) 1 (9)
*P < 0.05 versus control , **P < 0.001 versus control.DM2 groups were found for weight, BMI, fasting glucose
and insulin, and A1c (Table 1).
Markers of inflammation
Baseline levels of CRP were higher in the PL and MMPI
groups (P < 0.05; Table 2) compared to controls. There
was no significant change in CRP in the PL group
(P = 0.8) but a significant decrease in CRP in the MMPI
group from D1 to D84 (P < 0.05; Table 2; Figure 1). Base-
line levels of MPO were significantly higher in the PL
and MMPI groups on D1 and in the PL group on D84
compared to controls (Figure 1). MPO in the PL group
did not change significantly between D1 and D84
(P = 0.4). MPO significantly decreased in the MMPI
group from D1 to D84 (P = 0.001; Table 2; Figure 1).
There was no significant change from D1 to D84 for
cytokines in the PL or MMPI groups except for a signifi-
cant decrease in IL-10 in the PL group (P < 0.04; Table 2).
Insulin signaling
There was no difference between the participants in the PL
(n=7) or MMPI group (n=7) for age (54.0±7.1y; 56. ±5.3y),
weight (120.8±22.7 kg; 113.7±35.2 kg), BMI (40.0±6.2 kg/m2;
35.7±7 kg/m2) or A1c (9.0 ±1.5%; 7.7± 1.7%) for which
muscle was assessed for activation of insulin signaling med-
iators. In the PL group, there were no statistically significant
differences in the phosphorylation status of PDK1, Akt, or
GSK3β from D1 to D84 (Figure 2). In contrast, in the
MMPI group there was a statistically significant increase in
the phosphorylation status of PDK1, Akt, and GSK3β on
D84 compared to D1 (Figure 2).
Vital signs and lipids
There was no significant change in systolic or diastolic
blood pressure from D1 to D84 in the PL or MMPI group
(Table 2). There was no significant change in any param-
eter of the lipid profile for the MMPI group (Table 2). In
the PL group, total cholesterol decreased significantly
(P= 0.015) as did HDL (P= 0.009) from D1 to D84. There
was no significant change in triglycerides (P= 0.3) or LDL
(P= 0.08) in the PL group from D1 to D84.
AST and creatinine
There was no significant change in creatinine level in
the PL (P = 1.0) or MMPI group (P = 0.7; Table 2) or
AST level in the PL (P = 0.6) or MMPI group (P = 0.1;
Table 2) from D1 to D84.
Body composition
There was no significant change in weight in the PL
(121.6± 6.4 vs. 122.6 ± 6.4 kg) or MMPI group
(125.4± 12.2 vs. 126.7 ± 12.7 kg; P= 0.2 for both), lean
mass in the PL (75.5 ± 15.3 vs. 74.5± 14.1 kg) or MMPI
Table 2 Outcome measures on D1 and D84 (Mean± SEM)
Placebo Group (n= 11) MMPI Group (n =9)Measures Control
D1 D84 D1 D84
CRP 1.9 ± 0.8 5.9 ± 1.8* 6.2 ± 1.8* 7.4 ± 3.3* 2.3 ± 0.4†
MPO 68.8 ± 6.6 88.6 ± 6.0* 94.5 ± 11.3* 110.2 ± 15.3* 91.6 ± 13.6†
SBP (mmHg) 115.7 ± 19.6 127.7 ± 5.7 133.4 ± 4.8 136.2 ± 6.5 137.5 ± 5.8
DBP (mmHg) 72.0 ± 10.5 77.0 ± 10.1 77.8 ± 11 77.8 ± 8.0 77.4 ± 11.2
TC (mg/dL) 177.5 ± 28.0 178.8 ± 13 152.2 ± 6 177.9 ± 14 165.1 ± 10
HDL (mg/dL) 54.0 ± 15.2 40.5 ± 3.2** 36.58 ± 3.0** 38.44 ± 2.6** 38.44 ± 3.2**
LDL (mg/dL) 106.7 ± 22.2 99.6 ± 12 82 ± 7 86± 9 86.4 ± 8.8
TG (mg/dL) 84.4 ± 39.0 209.1 ± 30** 191.5 ± 36** 235.9 ± 48** 188.6 ± 37**
AST (IU/L) 22.8 ± 7.7 30.8 ± 4.1 33.0 ± 6.1 24.4 ± 2.9 20.1 ± 1.4
Creatinine (mg/dL) 0.9 ± 0.2 0.83 ± 0.05 0.83 ± 0.07 0.91 ± 0.05 0.92 ± 0.06
Fasting glucose (mmol/L) 5.1 ± 1.2 9.4 ± 0.5** 8.8 ± 0.6** 8.0 ± 0.7** 8.0 ± 1.0**
A1C (%) 5.4 ± 0.2 8.6 ± 0.4 8.0 ± 0.3 8.3 ± 0.6 7.8 ± 0.4
AUCi 0.25 ± 0.07 0.57 ± 0.16 0.57 ± 0.13* 0.89 ± 0.31* 0.71 ± 0.29
HOMA-IS 53.4 ± 7.6 135.3 ± 32.7 164 ± 46.8 244.9 ± 98.5 433.1 ± 272.1
HOMA-IR 1.06 ± 0.1 21 ± 5.1 26 ± 9.8 14.3 ± 4.7 23.0 ± 11.1
ΔI30–0/ΔG30–0 98 ± 17.5 37.3 ± 51.1 54.3 ± 30 73.7 ± 35.9 16.6 ± 20.1†
Global MMP (uM 5-FAM/h-ug protein) 47.2 ± 3.2 43.8 ± 4 56.6 ± 10.1 56.8 ± 13.3 59.7 ± 4.3
IL-1β (pg/ml) 0.15 ± 0.06 0.14 ± 0.05 0.13 ± 0.04 0.27 ± 0.15 0.46 ± 0.22
IL-2 (pg/ml) 1.8 ± 0.6 1.1 ± 0.4 0.9 ± 0.3 0.7 ± 0.3 1.1 ± 0.4
IL-4 (pg/ml) 10.0 ± 2.5 7.3 ± 2.1 9.9 ± 4.5 9.8 ± 4.2 7.4 ± 2.3
IL-6 (pg/ml) 6.9 ± 1.5 5.3 ± 1.9 8.4 ± 3.5 10.9 ± 4.3 12.9 ± 5.4
IL-8 (pg/ml) 2.4 ± 0.4 2.8 ± 0.5 3.2 ± 0.5 4.8 ± 0.9 5.8 ± 1.0
IL-10 (pg/ml) 16.6 ± 3.8 15.1 ± 3.5 11.3 ± 3.0† 16.4 ± 5.2 16.8 ± 3.8
TNF-α (pg/ml) 4.7 ± 0.6 4.4 ± 0.4 4.4 ± 0.7 6.6 ± 1.3 5.8 ± 1.1
*P < 0.05 versus control, **P < 0.01 versus control, †P< 0.05 vs. D1.
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mass in the PL (40.7 ± 10.3 vs. 41.5± 10.1) or MMPI group
(37.8 ± 13.3 vs. 39.8± 15.1 kg; P = 0.3 for both) between D1
and D84.
Glucose homeostasis
The fasting glucose level was significantly lower in the
control group compared to the MMPI and PL groups on
D1 and D84 (Table 2). There was no significant change
in A1c between D1 and D84 for the PL or MMPI group
(Table 2). The mean percent change in A1c values be-
tween the MMPI and PL groups was not significantly
different (data on file; P = 0.6). The AUCi did not change
from D1 to D84 for the PL or MMPI groups (Table 2).
The AUCi for the PL group was not significantly differ-
ent compared to the control group on D1 but became
significantly higher at D84 (Table 2). The AUCi for the
MMPI group was significantly higher than the control
group at D1 but became non-significantly different at
D84 (Table 2). There was no change in the ΔI30–0/ΔG30–0 in the PL group from D1 to D84. The ΔI30–0/
ΔG30–0 significantly decreased in the MMPI group
from D1 to D84 (Table 2). There was no significant dif-
ference for HOMA-IS for the PL group at D1 compared
to D84 (P = 0.4; Table 2). The HOMA-IS trended higher
for the MMPI group on D84 compared to D1 (P = 0.05;
Table 2). There was no significant change in the
HOMA-IR for the PL (P = 0.4) or MMPI groups
(P = 0.07) from D1 to D84 (Table 2).
MMP level and activity
There was no difference in global MMP level between
the control group and the PL or MMPI groups on D1 or
D84, and no change in the global MMP level in the PL
or MMPI groups from D1 to D84 (Table 2).
MMP 2/9 activity was significantly lower in the con-
trol group compared to the PL and MMPI groups on
D1, and PL group on D84 (Figure 3). There was no dif-
ference in MMP 2/9 activity between the PL and MMPI
groups on D1 or D84 (Figure 3).
Figure 1 MPO and CRP levels for the Control, PL, and MMPI
groups. MPO and CRP levels for the Control group at D1, and the
PL and MMPI groups at D1 and D84. † P < 0.05 versus Control group.
# < 0.05 versus D1 of the MMPI group.
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This proof of concept study confirmed that in only
12 weeks, the MMPI, doxycycline, improved global mea-
sures of inflammation and muscle insulin sensitivity in
people with DM2.
Global markers of inflammation, CRP and MPO levels
in plasma, were significantly higher in obese participants
with diabetes before treatment compared to controls,
supporting the pro-inflammatory state expected in this
population. CRP is a global measure of inflammation
and oxidative stress even in apparently “healthy” popula-
tions [28] and MPO is a lysosomal enzyme in neutro-
phils that has been associated with coronary plaque
instability [29] and therefore increased cardiovascular
risk. [30] As expected, MPO levels have been shown to
be higher in people with diabetes compared to controls.
[31] MMPI treatment resulted in a significant decrease
in both CRP and MPO by the end of the study whereas
PL had no effect, supporting the anti-inflammatory
properties of doxycycline. While medications such asHMG coA reductase inhibitors (“statins”) or aspirin are
known to affect inflammatory markers (i.e. CRP, MPO),
participants did not change medications during the
study and so drug effects for our study participants
should have been stable. Other than a significant de-
crease in the anti-inflammatory cytokine IL-10 in the PL
group, there were no significant changes in cytokine
levels in the PL or MMPI group. Changes in expression
of cytokines after MMPI may be better measured in tis-
sues rather than blood.
To test for an effect of MMPI on insulin sensitivity,
three different kinases in the insulin signaling cascade in
muscle (PDK1, Akt, GSK3β) were examined in muscle
biopsies obtained directly after an OGTT (a relative
insulin-stimulated state). In the MMPI treated group,
there was a significant increase in the phosphorylation
status of all of three kinases, indicating an improvement
in the insulin sensitivity of the muscle, with no change
in the PL group. Data are needed to link the global de-
crease in inflammation with improved insulin sensitivity
in muscle.
Golub et al. first demonstrated inhibition of MMPs by
tetracyclines in people with diabetes. [14,17,32] The de-
cision to use doxycycline in this study was based on
these data, its broad spectrum MMPI [9,12,13], and its
successful MMPI in a number of pathological states [16]
including an animal model of diabetes. [9] The literature
provides additional evidence that doxycycline can inhibit
the activity of other classes of proteases such as plasmin
(a serine protease) [33], and act as an oxygen radical
scavenger. [34] Doxycycline is also known to be rela-
tively well tolerated with minor side-effects. This study
resulted in one case of sun sensitivity with doxycycline
use, two cases of nausea and one patient developed
serum sickness. Serum sickness like syndrome is known
to occur with the use of the tetracyclines, minocycline
[35] and doxycycline. [36]
Dosing schemes of MMPI vary widely from 40 mg daily
[37] and upwards, including the usual adult antibiotic
dose of 100 mg twice daily used in this proof of concept
study, a dose reported to reduce CRP levels during in-
flammation associated with infection [38]. That doxycyc-
line improved insulin sensitivity in muscle but not global
glucose homeostasis in people with DM2 suggests the
need for larger and longer clinical trials, as well as a dose
finding study as lower amounts of doxycycline (40 mg
daily) have been shown to significantly reduce CRP in
people with cardiovascular disease over 6 months [39].
The proposed mechanism by which doxycycline
improves insulin sensitivity, is by inhibition of inflamma-
tory MMPs that cleave the extracellular insulin receptor
domain, thereby inactivating the receptor. [9] Doxycyc-
line and other MMPI have been shown to inhibit cleav-
age of other receptors including vascular endothelial
Figure 2 Activation of muscle insulin signaling mediators in PL and MMPI groups. MMPI but not PL improves insulin signaling in muscle.
Left side panels, A, B and C are digital representations of western immunoblots of key mediators in the insulin signaling pathway (PDK1, Akt,
GSK3β. Amounts of phosphorylated and total PDK-1 (A), Akt (B) and GSK3-β (C) in MMPI and PL participants were analyzed at D1 (labeled B on
blots) and D84 (labeled A on blots). Specimens for this analysis were obtained from muscle biopsies of seven consecutive age-matched PL and
MMPI subjects. In the right side panel, the data is presented as fold change from D1 to D84 in the percentage of phosphorylated (activated) to
total molecules in the PL and MMPI groups.
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find a difference in global MMP levels between control
participants and those with DM2, and no change in glo-
bal MMP levels after MMPI; this may be due to the rela-
tively low sensitivity of this technique. Using a new and
more sensitive technology to measure MMP 2/9 activity,
[21] we found higher MMP 2/9 activity levels in all
obese study participants with diabetes compared to the
control group prior to treatment, in agreement withothers. [2,19,41] This difference is likely due to the
higher sensitivity of the electrophoretic zymographic
technique and the fact that it does not require separ-
ation of blood cells from plasma. [21] However, we
found no significant effect of doxycycline on blood levels
of MMP 2/9 activity at study completion using this new
technique. We hypothesize that although we found
improvements in insulin sensitivity, the time of the study
was not long enough to see a reduction in these MMP
Figure 3 MMP 2/9 activity in the Control, PL, and MMPI groups.
MMP 2/9 activity in the Control group (D1) and PL and MMPI
groups (D1 and D84). Activity was measured after mixing plasma
with a charge-changing peptide substrate for MMP-2 and MMP-9
followed by electrophoresis (see Methods). *P = 0.001 versus the
control group.
Frankwich et al. Journal of Inflammation 2012, 9:35 Page 8 of 10
http://www.journal-inflammation.com/content/9/1/35levels in people with severe insulin resistance, and that
gene expression of MMPs and TIMP levels need to be
measured along with MMPs. During our study, it was
reported that blood MMP 2/9 activity levels do not
change in participants with DM2 during an OGTT. [42]
It appears that MMP blood activity, at present, could be
more useful in screening for whether a patient should
take MMPI (after observing elevated MMP activity), but
isn’t as sensitive for monitoring the effect of treatment
after a glucose load. It may require a stronger stimulus
than glucose alone, such as a mixed meal, to induce
measureable changes in MMP levels in the blood.
There are many factors that can affect MMP activity
in blood, in addition to DM2. The development of more
specific protease substrates that better differentiate the
activity from individual types of MMPs and other pro-
teases would be useful in studies such as these. From
animal and in vitro studies, it may be that the best way
to measure the effect of MMPI on MMP activity is not
through blood samples but in tissues such as adipose tis-
sue, where MMP activity is increased in obesity and tis-
sue inhibitors of MMPs (TIMPs) are decreased. [2]
Studies are ongoing to test whether MMPI can affect
MMP and TIMP levels, and insulin receptor integrity in
humans.
Commonly measured clinical parameters of DM con-
trol were evaluated in this study including weight, A1c,
triglycerides, and blood pressure which did not change in
either the MMPI or PL groups. The early secretory re-
sponse of insulin to an oral glucose load, however, was
significantly lower after MMPI treatment as was the se-
cretion of insulin measured by the HOMA-IS, and theAUCi was improving in the MMPI group but not the PL
group. While there was a significant increase in activa-
tion of molecules in the insulin signaling pathways dur-
ing this period, the time it takes to see a clinically
significant effect on overall glucose control is likely
longer. Improvements in global measures of glucose
homeostasis by MMPI required 6 months in rats [9] and
may be even longer in a more genetically mixed popula-
tion of people. DM2 participants in this trial were on
antihypertensive, lipid lowering and hypoglycemic medi-
cations which may have affected changes in insulin sensi-
tivity. Larger numbers of participants with both new
onset DM or impaired glucose tolerance or impaired
fasting glucose with minimal medication use and a longer
trial will be important in determining if there are any
benefits to MMPI use in the treatment of inflammation
and reduced insulin sensitivity in humans. If doxycycline
were to be used long-term, studies on development of re-
sistance or changes in gastrointestinal flora would be
helpful to understand the contribution of these changes
to markers of inflammation and insulin sensitivity. Add-
itional limitations of this study include the lack of assess-
ment of tissue MMPs, and small study size.
Conclusions
Treatment of obese diabetics with doxycycline for
12 weeks significantly decreased serum markers of in-
flammation while increasing muscle tissue insulin sensi-
tivity; these data suggest that longer studies in people
should be explored. Studies with larger numbers of
patients, longer treatment periods of escalating doses of
doxycycline and a detailed evaluation of the underlying
mechanisms leading to improvements in inflammation
and insulin sensitivity may provide greater insight into
the potential for using doxycycline and other MMP inhi-
bitors in human disease.
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